Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.44 |
| ▸ | NQO1 | P15559 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11230576 | 0.94 | ELANE (0.44) | ELANENQO1ALDH1A1MEN1ABCB11 | |
| SCHEMBL9502514 | 0.82 | ELANE (0.49) | ELANENQO1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4867725 | 0.80 | ELANE (0.47) | ELANENQO1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL28351931 | 0.75 | ELANE (0.46) | ELANENQO1ALDH1A1PKMKDM4E | |
| SCHEMBL10795690 | 0.73 | NQO1 (0.48) | NQO1ALDH1A1MEN1ABCB11LMNA | |
| SCHEMBL5613862 | 0.71 | NQO1 (0.40) | ELANENQO1ALDH1A1MEN1ABCB11 | |
| SCHEMBL2554785 | 0.70 | GABRA1 (0.50) | ELANEGABRA1GABRB2 | |
| SCHEMBL10791541 | 0.69 | HSD17B3 (0.46) | NQO1ALDH1A1MEN1ABCB11LMNA | |
| Hydrochloric Acid SCHEMBL10351311 | 0.68 | GABRA1 (0.48) | ELANEGABRA1GABRB2 | |
| SCHEMBL10794643 | 0.68 | MAPT (0.52) | NQO1ALDH1A1MEN1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356356-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | Senomyx, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9188590-B2 | Labeled transition metal complexes | LEICA BIOSYSTEMS NEWCASTLE LTD. (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110207123-A1 | METHOD FOR DETECTING CHROMOSOMAL ABNORMALITIES | ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (FR) | 2011-08-25 | — | — | US | disclosed |
| US-20110065687-A1 | HYDRAZIDE COMPOUNDS AND USES THEREOF | SENHWA BIOSCIENCES, INC. (TW) | 2011-03-17 | — | — | US | disclosed |
| EP-1828777-B1 | LABELED TRANSITION METAL COMPLEXES | KREATECH BIOTECH BV (NL) | 2011-03-02 | — | — | EP | disclosed |
| US-7816406-B2 | Quinolone analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100155590-A1 | LABELED TRANSITION METAL COMPLEXES | KREATCH BIOTECHNOLOGY B.V. (NL) | 2010-06-24 | — | — | US | disclosed |
| US-20100063046-A1 | TETRACYCLIC IMIDAZOLE ANALOGS | SENHWA BIOSCIENCES, INC. (TW) | 2010-03-11 | — | — | US | disclosed |
| US-7612063-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| WO-2006062391-A1 | LABELED TRANSITION METAL COMPLEXES | KREATECH BIOTECHNOLOGY B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| US-20060074089-A1 | Quinolone analogs | SENHWA BIOSCIENCES, INC. (TW) | 2006-04-06 | — | — | US | disclosed |
| WO-2006034113-A2 | QUINOLONE ANALOGS AS CELL PROLIFERATION INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060029950-A1 | Substituted quinobenzoxazine analogs and methods of using thereof | CYLENE PHARMACEUTICALS, INC. | 2006-02-09 | — | — | US | disclosed |
| EP-1610759-A2 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | Cylene Pharmaceuticals, Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1610795-A2 | HETEROCYCLIC SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE ANALOGS | Cylene Pharmaceuticals, Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050085468-A1 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS | 2005-04-21 | — | — | US | disclosed |
| US-20050004160-A1 | Heterocyclic substituted 1,4-dihydri-4-0x9-1,8-naphthyridine analogs | CYLENE PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004091627-A2 | HETEROCYCLIC SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004091504-A2 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085468-A1 | Substituted quinobenzoxazine analogs | CYP3A5, UGT2B7, CYP2D6 | ELANE 743/4885NQO1 30/4885ALDH1A1 553/4885 |
| US-20050004160-A1 | Heterocyclic substituted 1,4-dihydri-4-0x9-1,8-naphthyridine analogs | CYP2C9, CYP4X1, UGT1A9 | ELANE 2378/4885NQO1 22/4885ALDH1A1 282/4885 |
| US-20100063046-A1 | TETRACYCLIC IMIDAZOLE ANALOGS | BAD, API5, MCL1 | ELANE 2962/4885NQO1 1382/4885ALDH1A1 3035/4885 |
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYP3A5, UGT2B7, CYP2D6 | ELANE 743/4885NQO1 30/4885ALDH1A1 553/4885 |
| US-20060074089-A1 | Quinolone analogs | NQO2, BAX, MCL1 | ELANE 2340/4885NQO1 7/4885ALDH1A1 2050/4885 |
| US-20100155590-A1 | LABELED TRANSITION METAL COMPLEXES | CD63, ABCB7, TMT1A | ELANE 3539/4885NQO1 317/4885ALDH1A1 915/4885 |
| US-20110065687-A1 | HYDRAZIDE COMPOUNDS AND USES THEREOF | EIF2AK2, DDX21, POLI | ELANE 3049/4885NQO1 1088/4885ALDH1A1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.